 |
 |
Some good news on GDNF There's an interview with Dr. Erich Mohl. CEO of MedGenesis on the development of an old/ new GDNF treatment for Parkinson's. This is the Canadian company that managed to get the license to Amgen's GDNF protein. They are working on convection enhanced deiivery using a port instead of a pump.Hoping for phase II trials to start in feb. 2011. Andy Grove is one of the major investors. see full article at http://biotuesday.ca/?p=2534&upm_export=pdf ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn